Dr. Jacob Udell
Cardiologist | University Health Network
Toronto, ON, CANADA
Dr. Udell’s research focus is on cardiovascular outcomes studies
Media
Publications:
Documents:
Videos:
Audio/Podcasts:
Biography
Dr. Jacob (Jay) Udell is a Staff Cardiologist within the Department of Medicine at Women’s College Hospital and the University Health Network, and a Clinician Scientist at the Women’s College Research Institute and University of Toronto Faculty of Medicine. Dr. Udell’s research focus is on cardiovascular outcomes studies, with an emphasis on a) sex-based differences in risk and response to therapy; and b) innovative cardiac risk evaluation and models of care.
Dr. Udell completed his M.D. at the University of Toronto (2003) and a Master of Public Health as a Fulbright Scholar at the Harvard School of Public Health (2005). He went on to complete training in internal medicine at the University of British Columbia (2007), general internal medicine with a focus on maternal medicine at the University of Toronto (2008), and then cardiology at Brigham and Women’s Hospital and Mass. General Hospital, Harvard Medical School (2011). Dr. Udell is certified by the Royal College of Physicians and Surgeons in internal medicine (2008) and cardiology (2011). He is also board certified in internal medicine by the American Board of Internal Medicine (2008) and echocardiography by the American Society of Echocardiography (2013).
Industry Expertise (5)
Women
Research
Health and Wellness
Education/Learning
Architecture and Planning
Areas of Expertise (5)
Cardiovascular Disorders
Women's Health
Comparative Effectiveness Research
Screening and Prevention
Knowledge Translation
Accomplishments (4)
Heart and Stroke Foundation Emerging Researcher Leaders Initiative (ELRI) grant (personal)
This grant supports emerging research leaders early in their careers
Heart and Stroke Foundation Ontario Clinician - Sceintist Award (personal)
This award is given to clinician-scientists who have proven the ability to develop research with impact related to cardiovascular / cerebrovascular disease.
Heart and Stroke Foundation National New Investigator Award (personal)
This award is a salary award to support new investigators who have demonstrated excellence in their pre- and post- doctoral training and wish to establish their own laboratory.
Canadian Institutes in Health Research - Rising Star Award (professional)
The organization recognized three physicians from across Canada for innovative research. Dr. Udell examined the benefits of flu vaccines for cardiac patients.
Education (5)
University of Toronto: MD 2003
Harvard School of Public Health: MPH 2005
Fulbright Scholar
York University: BSc
University of Toronto and University of British Columbia: FRCPC, Internal Medicine
Harvard Medical School: FRCPC, Cardiology
Brigham and Women's Hospital
Affiliations (2)
- University of Toronto : Lecturer and Clinician - Scientist Department of Medicine
- Women's College Research Institute : Post-Doctoral Fellow
Media Appearances (3)
PMCC Cardiologist Wins National Award
UHN
2014-06-24
Dr. Jacob Udell, cardiologist at the Peter Munk Cardiac Centre and Women's College Hospital, won the Rising Star Award in May 2014 from the Canadian Institutes in Health Research (CIHR). The organization recognized three physicians from across Canada for innovative research. Dr. Udell examined the benefits of flu vaccines for cardiac patients.
Jacob Udell, MD, MPH, FRCPC
Women's College Research Institute
Dr. Udell is a cardiologist at Women’s College Hospital, clinician-scientist at the Women’s College Research Institute and an assistant professor of medicine at the University of Toronto.
The dismal odds of surviving a sudden cardiac arrest
Windsor Star
The shocking recent deaths of two prominent, apparently healthy men in their 40s underscores the “really, really poor” odds you’ll survive a sudden cardiac arrest — 10 per cent — when it happens outside a hospital.
Articles (3)
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction
Oxford University Press
2015 "Aims : Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a variety of patient populations, with heterogeneous results regarding benefit and safety, specifically with regard to cardiovascular and non-cardiovascular mortality. We performed a meta-analysis of randomized trials comparing more than a year of DAPT with aspirin alone in high-risk patients with a history of prior myocardial infarction (MI)."
Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR - TIMI 53 Randomized Trial
American Heart Association Journal
2014 "Background : Diabetes and heart failure frequently coexist. However, few diabetes trials have prospectively evaluated and adjudicated heart failure as an endpoint. "
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
The New England Journal of Medicine
2013 "Background: Type 2 diabetes mellitus doubles the risk of major cardiovascular complications in patients with and in patients without established cardiovascular disease,1-3 such that the majority of patients with diabetes die of cardiovascular diseases.4 Although improved glycemic control has repeatedly been shown to reduce microvascular diabetic complications,5 uncertainty remains regarding whether any particular glucose-lowering strategy, or specific therapeutic agent, is safe from a cardiovascular standpoint or can actually lower cardiovascular risk. With the possible exception of trials of metformin6 and insulin,7 most reported trials to date evaluating the effects on cardiovascular outcomes of specific glucose-lowering strategies or medications either have been insufficiently powered or have shown no significant cardiovascular benefit8-10 or an increased risk of death11 or heart failure.12-15 Thus, there remains a strong clinical need to identify antihyperglycemic agents that are, at a minimum, safe and that can potentially reduce cardiovascular complications. Moreover, in 2008, the Food and Drug Administration and the European Medicines Agency simultaneously revised their approval processes for all new glucose-lowering therapies to require a demonstration of cardiovascular safety.16 Saxagliptin (Onglyza, AstraZeneca and Bristol-Myers Squibb) is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor. 17 In phase 2–3 studies, treatment with saxagliptin improved glycemic control as compared with placebo and in pooled analyses reduced the risk of major cardiovascular events.18 The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 trial was designed to evaluate the safety and efficacy of saxagliptin with respect to cardiovascular outcomes in patients with diabetes mellitus who are at risk for cardiovascular events. "